HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A new topoisomerase-II inhibitor, BE-10988, produced by a streptomycete. I. Taxonomy, fermentation, isolation and characterization.

Abstract
A new topoisomerase inhibitor, BE-10988, was isolated from the culture broth of a strain of actinomycetes. The producing strain had a close resemblance to Streptomyces fimicarius and Streptomyces xanthocidicus. The active principle was extracted from the whole broth of strain BA10988 with ethyl acetate and purified by silica gel chromatography and by HPLC. BE-10988 increased DNA-topoisomerase complex formation and inhibited the growth of both doxorubicin-resistant and vincristine-resistant P388 murine leukemia cell lines, as well as sensitive P388 cell lines.
AuthorsH Oka, T Yoshinari, T Murai, K Kawamura, F Satoh, K Funaishi, A Okura, H Suda, M Okanishi, Y Shizuri
JournalThe Journal of antibiotics (J Antibiot (Tokyo)) Vol. 44 Issue 5 Pg. 486-91 (May 1991) ISSN: 0021-8820 [Print] England
PMID1648054 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Thiazoles
  • Topoisomerase II Inhibitors
  • BE 10988
Topics
  • Animals
  • Antineoplastic Agents (chemistry, isolation & purification, pharmacology)
  • Fermentation
  • Leukemia L1210 (drug therapy, enzymology, pathology)
  • Streptomyces (classification, isolation & purification, metabolism)
  • Thiazoles (isolation & purification, pharmacology)
  • Topoisomerase II Inhibitors
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: